Obizur® (Antihemophilic Factor [Recombinant], Porcine Sequence)

Obizur is covered only for on‑demand treatment, control (and guideline‑supported prevention) of bleeding episodes in adults (≥18 years) with acquired hemophilia A and is not covered for other diagnoses (e.g., congenital hemophilia A, pediatric/other bleeding disorders). Coverage requires prescribing by or consultation with a hemophilia specialist, initial dosing of 200 units/kg with titration based on factor VIII recovery and clinical response, documentation of diagnosis/age/dosing/response/factor VIII levels and applicable safety criteria, and is approved for up to 12 months.

"On‑demand treatment and control of bleeding episodes in adults with acquired hemophilia A (FDA‑approved indication)."

Sign up to see full coverage criteria, indications, and limitations.